These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24711279)

  • 1. An integrated approach for detection and characterization of the trace impurities in levofloxacin using liquid chromatography-tandem mass spectrometry.
    Zheng YJ; He JM; Zhang RP; Wang YC; Wang JX; Wang HQ; Wu Y; He WY; Abliz Z
    Rapid Commun Mass Spectrom; 2014 May; 28(10):1164-74. PubMed ID: 24711279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impurity analysis and quality evaluation for commercial levofloxacin formulations using LC-MS/MS method].
    Zheng YJ; Zhang RP; Gao Y; Wang YC; Wang JX; He JM; Abliz Z
    Yao Xue Xue Bao; 2016 Mar; 51(3):444-9. PubMed ID: 29859027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.
    Thomas S; Shandilya S; Bharati A; Paul SK; Agarwal A; Mathela CS
    J Pharm Biomed Anal; 2012 Jan; 57():39-51. PubMed ID: 21880452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new trace related impurities in adenosine products using ultra-high-performance liquid chromatography/electrospray ionization quadrupole time-of-flight tandem mass spectrometry.
    Shen Y; Zhai P; Xi P; Chen C; Mou F; Li F; Zhang J
    Rapid Commun Mass Spectrom; 2019 Nov; 33(22):1739-1750. PubMed ID: 31146299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the trace-level impurities in the bulk drug citalopram by high-performance liquid chromatography/tandem multistage mass spectrometry.
    Sun C; Xu H; Pan Y; Shen Z; Wang D
    Rapid Commun Mass Spectrom; 2007; 21(17):2889-94. PubMed ID: 17663502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry.
    Wang D; Wynne C; Gu F; Becker C; Zhao J; Mueller HM; Li H; Shameem M; Liu YH
    Anal Chem; 2015 Jan; 87(2):914-21. PubMed ID: 25513708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel process-related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR.
    Zhu P; Yang W; Hong L; Cheng Q; Luo L; He J; Chen J
    J Pharm Biomed Anal; 2015 Mar; 107():437-43. PubMed ID: 25666544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.
    Schneider A; Wessjohann LA
    J Pharm Biomed Anal; 2010 Nov; 53(3):767-72. PubMed ID: 20570457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis.
    Zhang LK; Yang R; Sheng H; Helmy R; Zheng J; Cao Y; Gauthier DR
    J Mass Spectrom; 2016 Oct; 51(10):959-968. PubMed ID: 27383410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of impurities in commercial spectinomycin by liquid chromatography with electrospray ionization tandem mass spectrometry.
    Wang Y; Wang M; Li J; Yao S; Xue J; Zou W; Hu C
    J Antibiot (Tokyo); 2014 Jul; 67(7):511-8. PubMed ID: 24736854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and comprehensive impurity profiling of synthetic thyroxine by ultrahigh-performance liquid chromatography-high-resolution mass spectrometry.
    Neu V; Bielow C; Gostomski I; Wintringer R; Braun R; Reinert K; Schneider P; Stuppner H; Huber CG
    Anal Chem; 2013 Mar; 85(6):3309-17. PubMed ID: 23394260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation and characterization of clindamycin phosphate and related impurities in injection by liquid chromatography/electrospray ionization mass spectrometry.
    Wang SM; Bu SS; Liu HM; Li HY; Liu W; Wang YD
    Rapid Commun Mass Spectrom; 2009 Mar; 23(6):899-906. PubMed ID: 19222030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micellar electrokinetic chromatography-electrospray ionization mass spectrometry for the identification of drug impurities.
    Mol R; Kragt E; Jimidar I; de Jong GJ; Somsen GW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):283-8. PubMed ID: 16837254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of unknown impurities in Coenzyme Q
    Deng Y; Chen X; Wang L; Peng X; Lin M
    J Pharm Biomed Anal; 2019 Oct; 175():112771. PubMed ID: 31330281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.